View Webcasts

Questions and Scenarios for Medications for Opioid Use Disorder

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Jul 29, 2021
  • Expires: Jul 28, 2024
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)

Faculty

James D.  Hawthorne III James D. Hawthorne III, MD
Medical Director, Adult Inpatient Unit
UK Good Samaritan Hopsital
Assistant Professor, Psychiatry
University of Kentucky College of Medicine
Lexington, Kentucky

Needs Statement

Opioid use disorder is a commonly encountered disorder with high levels of associated morbidity and mortality. Medications for Opioid Use Disorder (MOUD) are an effective but underutilized treatment that can save lives and improve quality of life for patients with OUD. Increasing patient access to these medications can lead to significant improvement in outcomes for patients with OUD. 

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

  • Discuss naltrexone, buprenorphine, and methadone as evidence-based Medications for Opioid Use Disorder (MOUD)
  • Explain the mechanism of action, efficacy, side ​effects, dosing, and metabolism for each medication  
  • Discuss how to utilize these medications in patients with Opioid Use Disorder (OUD)

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Interpersonal and communication skills
  • Professionalism
  • Systems-based practice

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

CME-HB1

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This education activity is offered for a maximum of 1.0 ANCC pharmacology contact hours.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 1.2 KBN pharmacology contact hours.

Provider #: 3-0008-12-21-0165. In order to receive credit, participants complete CNE activity, complete the evaluation form. Certificates may be printed once the evaluation is completed.

Faculty Disclosure

No speaker, planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.

Attention: Please Read

Questions and Scenarios for Medications for Opioid Use Disorder enduring module is a recording from the live Regularly Scheduled Series dated February 25, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module.